Armata Pharmaceuticals, Inc.
AP-SA02
complicated S. aureus bacteremia
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for AP-SA02 in complicated S. aureus bacteremia are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 16h ago
“Highlighting positive results from the Phase 2a diSArm study of Armata's lead therapeutic phage candidate, AP-SA02, as a potential treatment for complicated SAB, at IDWeek 2025 TM .”